Dual Status Rx/OTC Plan B In The Works? Barr Weighs Its Options
This article was originally published in The Tan Sheet
Executive Summary
Barr hinted that it is leaning toward a dual label Rx/OTC approach in seeking FDA approval to switch the Plan B "morning after" pill
You may also be interested in...
FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs
FDA believes additional information on whether a drug can be marketed both Rx and OTC for the same indication is needed before a decision can be reached on Barr Labs' switch application for Plan B
FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs
FDA believes additional information on whether a drug can be marketed both Rx and OTC for the same indication is needed before a decision can be reached on Barr Labs' switch application for Plan B
FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs
FDA believes additional information on whether a drug can be marketed both Rx and OTC for the same indication is needed before a decision can be reached on Barr Labs' switch application for Plan B